<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89742</article-id><article-id pub-id-type="pmcid-ver">PMC89742.1</article-id><article-id pub-id-type="pmcaid">89742</article-id><article-id pub-id-type="pmcaiid">89742</article-id><article-id pub-id-type="pmid">10681334</article-id><article-id pub-id-type="doi">10.1128/aac.44.3.654-657.2000</article-id><article-id pub-id-type="publisher-id">0063</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Efficacy of Linezolid in Experimental Otitis Media</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pelton</surname><given-names initials="SI">S. I.</given-names></name><xref ref-type="aff" rid="N0x9883c80.0x9ddbf80">1</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Figueira</surname><given-names initials="M">M.</given-names></name><xref ref-type="aff" rid="N0x9883c80.0x9ddbf80">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Albut</surname><given-names initials="R">R.</given-names></name><xref ref-type="aff" rid="N0x9883c80.0x9ddbf80">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stalker</surname><given-names initials="D">D.</given-names></name><xref ref-type="aff" rid="N0x9883c80.0x9ddbf80">2</xref></contrib></contrib-group><aff id="N0x9883c80.0x9ddbf80"> Section of Pediatric Infectious Diseases, Maxwell Finland Laboratory for Infectious Diseases Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts,<sup>1</sup> and  Clinical Pharmacokinetics, Pharmacia &amp; Upjohn, Kalamazoo, Michigan<sup>2</sup></aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, 774 Albany St., Boston, MA 02118. Phone: (617) 414-7407. Fax: (617) 414-5806. E-mail: <email>spelton@bu.edu</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2000</year></pub-date><volume>44</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">2482</issue-id><fpage>654</fpage><lpage>657</lpage><history><date date-type="received"><day>28</day><month>1</month><year>1999</year></date><date date-type="rev-request"><day>23</day><month>7</month><year>1999</year></date><date date-type="accepted"><day>28</day><month>10</month><year>1999</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac000654.pdf"/><abstract><p>Therapy for otitis media (OM) due to resistant <italic>Streptococcus pneumoniae</italic> (MIC of penicillin, &#8805;2.0 &#956;g/ml) is challenging. Linezolid, an oxazolidinone, represent a new class of antimicrobial agents with excellent in vitro activity against penicillin-resistant <italic>S. pneumoniae</italic>; however, in vitro activity against nontypeable <italic>Haemophilus influenzae</italic> (NTHI) is limited. We evaluated its efficacy against experimental acute OM due to a multidrug-resistant <italic>S. pneumoniae</italic> isolate and two isolates of NTHI. The chinchilla model was utilized to evaluate the efficacy of linezolid against experimental infection due to <italic>S. pneumoniae</italic> or NTHI. Serum and middle ear antibiotic concentrations were determined, and sterilization of experimental OM was evaluated. Chinchillas were inoculated directly with <italic>S. pneumoniae</italic> into the superior bulla. Twenty-four hours after inoculation, all animals had positive middle ear and nasopharyngeal cultures. Animals were given linezolid at 25 mg/kg/dose twice a day (b.i.d.) by orogastric feeding tube or amoxicillin at 40 mg/kg/dose b.i.d. intramuscularly for 5 days. By day 5, all animals in the linezolid group had sterile middle ear cultures and eradication of <italic>S. pneumoniae</italic> from the nasopharynx. In the amoxicillin group, all nine animals remained middle ear and nasopharynx positive (<italic>P</italic> &lt; 0.01). In animals inoculated with NTHI, 25 and 37.5 mg/kg b.i.d. failed to sterilize middle ear infection or eradicate colonization. Mean levels in middle ear fluid measured during experimental infection were 12.8 &#956;g/ml at 2 to 6 h and 4.1 &#956;g/ml at 16 to 17 h after orogastric dosing at 25 mg/kg. Linezolid achieved a high concentration in the middle ear during experimental OM. Linezolid eradicated multidrug-resistant <italic>S. pneumoniae</italic> from the middle ear and nasopharynx. Experimental infection and nasopharyngeal colonization due to NTHI persisted despite achievement of concentrations in the middle ear that were above the MIC (for NTHI).</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>